Paul J. Emmerson
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, Regulation of Appetite and Obesity, Pharmacological Receptor Mechanisms and Effects, Diabetes Treatment and Management
Most-Cited Works
- → The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL(2017)634 cited
- → Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist(2020)445 cited
- → Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes.(1994)230 cited
- → Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.(1996)180 cited
- → GDF15 and Growth Control(2018)160 cited
- → Structural determinants of dual incretin receptor agonism by tirzepatide(2022)107 cited
- → Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist(2023)89 cited
- → The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling(2020)83 cited
- → Galanin Receptor-Mediated Inhibition of Glutamate Release in the Arcuate Nucleus of the Hypothalamus(1998)82 cited
- → Pre‐ and postsynaptic actions of opioid and orphan opioid agonists in the rat arcuate nucleus and ventromedial hypothalamus in vitro(1999)76 cited